{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:10:12Z","timestamp":1791839412887,"version":"4.3.4"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ZonMW Memorabel","award":["#733050824"],"award-info":[{"award-number":["#733050824"]}]},{"name":"ZonMW VIDI","award":["#09150171910068"],"award-info":[{"award-number":["#09150171910068"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Individuals with mild cognitive impairment (MCI) and an abnormal amyloid biomarker (A+) are at considerable increased risk of developing dementia. Still, these individuals vary greatly in rates of cognitive decline, and the mechanisms underlying this heterogeneity remain largely unclear. One factor related to an increased risk of progression to dementia is having an abnormal tau status (T+), but this still explains only part of the variance. Furthermore, previous work has indicated that MCI A+ individuals with T\u2013 or T+ are characterized by distinct molecular processes as reflected by distinct CSF proteomic profiles. As such, it could be hypothesized that differences in rates of cognitive decline in A+ MCI with abnormal or normal tau status may be explained by distinct underlying mechanisms. We studied this question using an untargeted CSF proteomic approach in individuals with MCI and abnormal amyloid.<\/jats:p>\n                  <jats:p>We measured untargeted Tandem Mass Tag (TMT) mass spectrometry proteomics in CSF of 80 A+ MCI individuals from the Amsterdam Dementia Cohort [age 66 \u00b1 7.9 years, 52 (65%) T+]. For each protein, we tested if CSF levels were related to time to progression to dementia using Cox survival models; and with decline on the Mini-Mental State Examination (MMSE) with linear mixed models, correcting for age, sex and education. We validated our results in the independent Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) that employed the orthogonal CSF Soma logic protein measures in 245 CSF A+ MCI individuals [age 73 \u00b1 7.2 years, 135 (55%) T+].<\/jats:p>\n                  <jats:p>In total, we found 664 (29%) proteins to be related to cognitive decline in A+T+ and 718 (31%) proteins in A+T\u2013. In A+T+, higher levels of 393 proteins that were associated with synaptic plasticity processes, and lower levels of 271 proteins associated with the immune function processes predicted a steeper decline on the MMSE and faster progression to dementia. In A+T\u2212, higher levels of 306 proteins that were related to blood\u2013brain barrier impairment and lower levels of 412 proteins associated with synaptic plasticity processes predicted a steeper decline; 67% of pathways associated with a decline in A+T+ and 58% in A+T\u2013 were replicated in ADNI.<\/jats:p>\n                  <jats:p>In conclusion, cognitive decline in A+ MCI individuals with and without tau may involve distinct underlying pathophysiology. These findings suggest that treatments aiming to delay cognitive decline may need tailoring according to the underlying mechanism of these patient groups, and that amyloid and tau levels could aid in stratification of selecting patients.<\/jats:p>","DOI":"10.1093\/brain\/awaf251","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T07:14:52Z","timestamp":1752822892000},"page":"4389-4399","source":"Crossref","is-referenced-by-count":4,"title":["CSF proteomic profiles related to cognitive decline in MCI A+ depend on tau levels"],"prefix":"10.1093","volume":"148","author":[{"given":"Eleonora M","family":"Vromen","sequence":"first","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc , Amsterdam, North-Holland 1081HZ ,","place":["The Netherlands"]},{"name":"Amsterdam Neuroscience, Neurodegeneration , Amsterdam, North-Holland 1081HZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8410-5078","authenticated-orcid":false,"given":"Diederick M","family":"de Leeuw","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc , Amsterdam, North-Holland 1081HZ ,","place":["The Netherlands"]},{"name":"Amsterdam Neuroscience, Neurodegeneration , Amsterdam, North-Holland 1081HZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argonde C","family":"van Harten","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc , Amsterdam, North-Holland 1081HZ ,","place":["The Netherlands"]},{"name":"Amsterdam Neuroscience, Neurodegeneration , Amsterdam, North-Holland 1081HZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-0837","authenticated-orcid":false,"given":"Charlotte E","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Amsterdam Neuroscience, Neurodegeneration , Amsterdam, North-Holland 1081HZ ,","place":["The Netherlands"]},{"name":"Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc , Amsterdam, North-Holland 1081HZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8766-6224","authenticated-orcid":false,"given":"Wiesje M","family":"van der Flier","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc , Amsterdam, North-Holland 1081HZ ,","place":["The Netherlands"]},{"name":"Amsterdam Neuroscience, Neurodegeneration , Amsterdam, North-Holland 1081HZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter Jelle","family":"Visser","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc , Amsterdam, North-Holland 1081HZ ,","place":["The Netherlands"]},{"name":"Amsterdam Neuroscience, Neurodegeneration , Amsterdam, North-Holland 1081HZ ,","place":["The Netherlands"]},{"name":"Alzheimer Centrum Limburg, Department of Psychiatry, Maastricht University , Maastricht, Limburg 6200 MD ,","place":["The Netherlands"]},{"name":"Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet , Stockholm 171 77 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-1797","authenticated-orcid":false,"given":"Betty M","family":"Tijms","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc , Amsterdam, North-Holland 1081HZ ,","place":["The Netherlands"]},{"name":"Amsterdam Neuroscience, Neurodegeneration , Amsterdam, North-Holland 1081HZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"2025120411073426800_awaf251-B1","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"2025120411073426800_awaf251-B2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/alz.12618","article-title":"Biofluid-based biomarkers for Alzheimer\u2019s disease-related pathologies: An update and synthesis of the literature","volume":"18","author":"Zetterberg","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2025120411073426800_awaf251-B3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: Towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"key":"2025120411073426800_awaf251-B4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1212\/WNL.0b013e3182704056","article-title":"Injury markers predict time to dementia in subjects with MCI and amyloid pathology","volume":"79","author":"van Rossum","year":"2012","journal-title":"Neurology"},{"issue":"Pt 5","key":"2025120411073426800_awaf251-B5","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/brain\/awv029","article-title":"Prevalence and prognosis of Alzheimer\u2019s disease at the mild cognitive impairment stage","volume":"138","author":"Vos","year":"2015","journal-title":"Brain"},{"key":"2025120411073426800_awaf251-B6","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","article-title":"Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype","volume":"15","author":"Vermunt","year":"2019","journal-title":"Alzheimers Dement"},{"key":"2025120411073426800_awaf251-B7","doi-asserted-by":"crossref","first-page":"e2673","DOI":"10.1212\/WNL.0000000000012022","article-title":"Finding treatment effects in Alzheimer trials in the face of disease progression heterogeneity","volume":"96","author":"Jutten","year":"2021","journal-title":"Neurology"},{"key":"2025120411073426800_awaf251-B8","doi-asserted-by":"crossref","first-page":"e12240","DOI":"10.1002\/trc2.12240","article-title":"CSF proteomic signature predicts progression to Alzheimer\u2019s disease dementia","volume":"8","author":"Vromen","year":"2022","journal-title":"Alzheimers Dement (NY)"},{"key":"2025120411073426800_awaf251-B9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13024-022-00521-3","article-title":"Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer\u2019s disease","volume":"17","author":"Visser","year":"2022","journal-title":"Mol Neurodegener"},{"key":"2025120411073426800_awaf251-B10","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1038\/s41593-024-01737-w","article-title":"Proteomic changes in Alzheimer\u2019s disease associated with progressive A\u03b2 plaque and tau tangle pathologies","volume":"27","author":"Pichet Binette","year":"2024","journal-title":"Nat Neurosci."},{"key":"2025120411073426800_awaf251-B11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41591-020-0815-6","article-title":"Large-scale proteomic analysis of Alzheimer\u2019s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation","volume":"26","author":"Johnson","year":"2020","journal-title":"Nat Med"},{"key":"2025120411073426800_awaf251-B12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41593-021-00999-y","article-title":"Large-scale deep multi-layer analysis of Alzheimer\u2019s disease brain reveals strong proteomic disease-related changes not observed at the RNA level","volume":"25","author":"Johnson","year":"2022","journal-title":"Nat Neurosci"},{"key":"2025120411073426800_awaf251-B13","doi-asserted-by":"crossref","first-page":"eaaz9360","DOI":"10.1126\/sciadv.aaz9360","article-title":"Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer\u2019s disease","volume":"6","author":"Higginbotham","year":"2020","journal-title":"Sci Adv"},{"key":"2025120411073426800_awaf251-B14","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1093\/brain\/awaa325","article-title":"Pathophysiological subtypes of Alzheimer\u2019s disease based on cerebrospinal fluid proteomics","volume":"143","author":"Tijms","year":"2020","journal-title":"Brain"},{"key":"2025120411073426800_awaf251-B15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s43587-023-00550-7","article-title":"Cerebrospinal fluid proteomics in patients with Alzheimer\u2019s disease reveals five molecular subtypes with distinct genetic risk profiles","volume":"4","author":"Tijms","year":"2024","journal-title":"Nat Aging"},{"key":"2025120411073426800_awaf251-B16","doi-asserted-by":"publisher","author":"Bangs","DOI":"10.1101\/2025.03.14.643332"},{"key":"2025120411073426800_awaf251-B17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3233\/JAD-170850","article-title":"Amsterdam dementia cohort: Performing research to optimize care","volume":"62","author":"van der Flier","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"2025120411073426800_awaf251-B18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J Intern Med"},{"key":"2025120411073426800_awaf251-B19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"2025120411073426800_awaf251-B20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer's Dement"},{"key":"2025120411073426800_awaf251-B21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2025120411073426800_awaf251-B22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","article-title":"Alzheimer\u2019s disease neuroimaging initiative (ADNI): Clinical characterization","volume":"74","author":"Petersen","year":"2010","journal-title":"Neurology"},{"key":"2025120411073426800_awaf251-B23","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer\u2019s disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"2025120411073426800_awaf251-B24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.43.2.250","article-title":"Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop","volume":"43","author":"Roma\u0301n","year":"1993","journal-title":"Neurology"},{"key":"2025120411073426800_awaf251-B25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.dadm.2017.04.007","article-title":"Consensus guidelines for lumbar puncture in patients with neurological diseases","volume":"8","author":"Engelborghs","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"key":"2025120411073426800_awaf251-B26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3233\/JAD-132306","article-title":"Optimizing patient care and research: The Amsterdam Dementia Cohort","volume":"41","author":"van der Flier","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"2025120411073426800_awaf251-B27","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","article-title":"A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking","volume":"73","author":"Teunissen","year":"2009","journal-title":"Neurology"},{"key":"2025120411073426800_awaf251-B28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1373\/clinchem.2009.130518","article-title":"Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease","volume":"56","author":"Mulder","year":"2010","journal-title":"Clin Chem"},{"key":"2025120411073426800_awaf251-B29","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1373\/clinchem.2017.281055","article-title":"Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-beta 1-42 analysis results","volume":"64","author":"Tijms","year":"2018","journal-title":"Clin Chem"},{"key":"2025120411073426800_awaf251-B30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1373\/clinchem.2004.039347","article-title":"Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology","volume":"51","author":"Olsson","year":"2005","journal-title":"Clin Chem"},{"key":"2025120411073426800_awaf251-B31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects","volume":"65","author":"Shaw","year":"2009","journal-title":"Ann Neurol"},{"key":"2025120411073426800_awaf251-B32","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1074\/mcp.M116.065524","article-title":"Extended multiplexing of tandem mass tags (TMT) labeling reveals age and high fat diet specific proteome changes in mouse epididymal adipose tissue","volume":"16","author":"Plubell","year":"2017","journal-title":"Mol Cell Proteomics"},{"key":"2025120411073426800_awaf251-B33","author":"Western"},{"key":"2025120411073426800_awaf251-B34","volume-title":"R: A language and environment for statistical computing. R foundation for statistical computing","author":"R Core Team","year":"2019"},{"key":"2025120411073426800_awaf251-B35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/75556","article-title":"Gene ontology: Tool for the unification of biology. The gene ontology consortium","volume":"25","author":"Ashburner","year":"2000","journal-title":"Nat Genet"},{"key":"2025120411073426800_awaf251-B36","doi-asserted-by":"crossref","first-page":"iyad031","DOI":"10.1093\/genetics\/iyad031","article-title":"The gene ontology knowledgebase in 2023","volume":"224","author":"Aleksander","year":"2023","journal-title":"Genetics"},{"key":"2025120411073426800_awaf251-B37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/pro.4218","article-title":"PANTHER: Making genome-scale phylogenetics accessible to all","volume":"31","author":"Thomas","year":"2022","journal-title":"Protein Sci"},{"key":"2025120411073426800_awaf251-B38","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1021\/acs.jproteome.8b00809","article-title":"Proteomes of paired human cerebrospinal fluid and plasma: Relation to blood-brain barrier permeability in older adults","volume":"18","author":"Dayon","year":"2019","journal-title":"J Proteome Res"},{"key":"2025120411073426800_awaf251-B39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.conb.2009.06.001","article-title":"Semaphorin function in neural plasticity and disease","volume":"19","author":"Pasterkamp","year":"2009","journal-title":"Curr Opin Neurobiol"},{"key":"2025120411073426800_awaf251-B40","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jalz.2016.01.010","article-title":"Genetic risk factors for the posterior cortical atrophy variant of Alzheimer\u2019s disease","volume":"12","author":"Schott","year":"2016","journal-title":"Alzheimers Dement"},{"key":"2025120411073426800_awaf251-B41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-022-01038-z","article-title":"P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles","volume":"14","author":"Wesenhagen","year":"2022","journal-title":"Alzheimers Res Ther."},{"key":"2025120411073426800_awaf251-B42","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/brain\/awac158","article-title":"Biomarker A+ T-: Is this Alzheimer\u2019s disease or not? A combined CSF and pathology study","volume":"146","author":"Vromen","year":"2023","journal-title":"Brain"},{"key":"2025120411073426800_awaf251-B43","doi-asserted-by":"crossref","first-page":"e12465","DOI":"10.1002\/trc2.12465","article-title":"Alzheimer\u2019s disease drug development pipeline: 2024","volume":"10","author":"Cummings","year":"2024","journal-title":"Alzheimer's Dement"},{"key":"2025120411073426800_awaf251-B44","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13195-022-01113-5","article-title":"Multi-platform proteomic analysis of Alzheimer\u2019s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome","volume":"14","author":"Dammer","year":"2022","journal-title":"Alzheimers Res Ther."}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awaf251\/63792077\/awaf251.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awaf251\/63792077\/awaf251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awaf251\/63792077\/awaf251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:07:45Z","timestamp":1764864465000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/148\/12\/4389\/8205833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,7,8]]},"published-print":{"date-parts":[[2025,12,4]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awaf251","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,7,8]]}}}